JP7701359B2 - 変形性関節症の治療方法 - Google Patents

変形性関節症の治療方法 Download PDF

Info

Publication number
JP7701359B2
JP7701359B2 JP2022534352A JP2022534352A JP7701359B2 JP 7701359 B2 JP7701359 B2 JP 7701359B2 JP 2022534352 A JP2022534352 A JP 2022534352A JP 2022534352 A JP2022534352 A JP 2022534352A JP 7701359 B2 JP7701359 B2 JP 7701359B2
Authority
JP
Japan
Prior art keywords
protein
nucleic acid
acid sequence
active fragment
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022534352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504201A5 (https=
JP2023504201A (ja
JPWO2021113642A5 (https=
Inventor
マルティネス レドンド、パロマ
ギレン－ギレン、イザベル
ベルモンテ、フアン カルロス イズピスア
デイヴィッドソーン、ノア
エム． チャーチ、ジョージ
ガルシア、ペドロ ギレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2023504201A publication Critical patent/JP2023504201A/ja
Publication of JP2023504201A5 publication Critical patent/JP2023504201A5/ja
Publication of JPWO2021113642A5 publication Critical patent/JPWO2021113642A5/ja
Priority to JP2025104155A priority Critical patent/JP2025126223A/ja
Application granted granted Critical
Publication of JP7701359B2 publication Critical patent/JP7701359B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2022534352A 2019-12-05 2020-12-04 変形性関節症の治療方法 Active JP7701359B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025104155A JP2025126223A (ja) 2019-12-05 2025-06-19 変形性関節症の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944027P 2019-12-05 2019-12-05
US62/944,027 2019-12-05
PCT/US2020/063319 WO2021113642A1 (en) 2019-12-05 2020-12-04 Methods for treating osteoarthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025104155A Division JP2025126223A (ja) 2019-12-05 2025-06-19 変形性関節症の治療方法

Publications (4)

Publication Number Publication Date
JP2023504201A JP2023504201A (ja) 2023-02-01
JP2023504201A5 JP2023504201A5 (https=) 2023-12-11
JPWO2021113642A5 JPWO2021113642A5 (https=) 2023-12-11
JP7701359B2 true JP7701359B2 (ja) 2025-07-01

Family

ID=76222269

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022534352A Active JP7701359B2 (ja) 2019-12-05 2020-12-04 変形性関節症の治療方法
JP2025104155A Pending JP2025126223A (ja) 2019-12-05 2025-06-19 変形性関節症の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025104155A Pending JP2025126223A (ja) 2019-12-05 2025-06-19 変形性関節症の治療方法

Country Status (8)

Country Link
US (1) US20230024183A1 (https=)
EP (1) EP4069313A4 (https=)
JP (2) JP7701359B2 (https=)
KR (1) KR20220119056A (https=)
CN (1) CN115515645A (https=)
AU (1) AU2020398637A1 (https=)
CA (1) CA3160033A1 (https=)
WO (1) WO2021113642A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250000512A (ko) 2023-06-27 2025-01-03 동신대학교산학협력단 요오드아세트산 나트륨 유도 골관절염에 양릉천과 현종 혈위를 자극하는 침습형 레이저침을 이용한 치료 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018098375A1 (en) 2016-11-22 2018-05-31 Klotho Therapeutics, Inc. Novel recombinant klotho proteins and compositions and methods involving the same
JP2019519221A (ja) 2016-05-20 2019-07-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 加齢関連疾患及び症状の遺伝子治療法
JP2019526272A (ja) 2016-06-02 2019-09-19 クロトー セラピューティクス インコーポレイテッドＫｌｏｔｈｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 治療用組換えクロトータンパク質ならびにそれを含む組成物および方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3548999A (en) * 1998-04-03 1999-10-25 Chiron Corporation Use of igfi for treating articular cartilage disorders
CA2330939A1 (en) * 1998-06-16 1999-12-23 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
NZ590667A (en) * 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019519221A (ja) 2016-05-20 2019-07-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 加齢関連疾患及び症状の遺伝子治療法
JP2019526272A (ja) 2016-06-02 2019-09-19 クロトー セラピューティクス インコーポレイテッドＫｌｏｔｈｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 治療用組換えクロトータンパク質ならびにそれを含む組成物および方法
WO2018098375A1 (en) 2016-11-22 2018-05-31 Klotho Therapeutics, Inc. Novel recombinant klotho proteins and compositions and methods involving the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AGING，2018年，Vol.10, No.6，pp.1442-1453

Also Published As

Publication number Publication date
KR20220119056A (ko) 2022-08-26
JP2023504201A (ja) 2023-02-01
US20230024183A1 (en) 2023-01-26
AU2020398637A1 (en) 2022-06-30
EP4069313A4 (en) 2024-02-28
EP4069313A1 (en) 2022-10-12
JP2025126223A (ja) 2025-08-28
CA3160033A1 (en) 2021-06-10
CN115515645A (zh) 2022-12-23
WO2021113642A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
CA2985935C (en) Fabry disease gene therapy
AU2018261003A1 (en) Compositions and methods of treating Huntington's Disease
US12194108B2 (en) Gene therapeutics for treating bone disorders
JP2019504003A (ja) 家族性高コレステロール血症を処置するための遺伝子治療
JP2021532810A (ja) 糖原病ｉｉｉの処置のためのミニｇｄｅ
JP2025126223A (ja) 変形性関節症の治療方法
US11077208B2 (en) Wilson's disease gene therapy
CN113557010A (zh) 用于递送治疗剂的腺相关病毒载体
EP4410988A1 (en) An aav2-vector variant for targeted transfer of genes
CN116323941A (zh) 通过诱导抗肌萎缩蛋白相关蛋白调节元件内的突变增强细胞中抗肌萎缩蛋白相关蛋白表达及其治疗用途
US20230265427A1 (en) Treatment of Genetic Dilated Cardiomyopathies
WO2009071679A1 (en) Novel aav vector and uses thereof
TW202216186A (zh) 用於治療同種異體移植物血管病變之組成物與方法
US20250327080A1 (en) Rnas targeting activin a subunits
Li Optimization of Adeno-associated Virus Vectors Encoding Immune Checkpoint Protein for Arthritis Gene Therapy
WO2025259575A1 (en) Methods and compositions for treatment of duchenne muscular dystrophy
WO2026030377A1 (en) Nfat1-based therapeutics for joint diseases
WO2026074284A1 (en) Methods of transducing podocytes
WO2024097521A2 (en) Compositions for treatment of osteogenesis imperfecta
WO2023288325A2 (en) Recombinant reelin gene therapy
HK40032412A (en) Capsid-modified, raav3 vector compositions and uses in gene therapy of human liver cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250520

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250619

R150 Certificate of patent or registration of utility model

Ref document number: 7701359

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150